Stem Cell Center Of NJ – New Jersey Stem Cell Therapy

Connect With Us On Social Media for Website Specials Today!

Shoulder pain from injuries can either be acute or chronic. Regenerative medicine is an emerging field, which offers a non-surgical option that commonly uses the patients own stem cells, exosomes, and other sources of growth factors to regenerate healthy tissue.

Your back pain has finally caught up with you and youre struggling to reverse the damage. However, regenerative medicine is an emerging field, which offers a non-surgical option that commonly uses the patients own stem cells, exosomes, and other sources of growth factors to regenerate healthy tissue.

If knee pain is derailing your active lifestyle or even your daily activities, then youre not alone. Regenerative medicine is an emerging field, which offers a non-surgical option that commonly uses the patients own stem cells, exosomes, and other sources of growth factors to regenerate healthy tissue.

Pain can strike in a few locations around the hip. Regenerative medicine is an emerging field, which offers a non-surgical option that commonly uses the patients own stem cells, exosomes, and other sources of growth factors to regenerate healthy tissue.

NERVE INJURIES pain doesnt fade, your health care provider may recommend surgery to reverse the damage. However, regenerative medicine is an emerging field, which offers a non-surgical option that commonly uses the patients own stem cells, exosomes, and other sources of growth factors to regenerate healthy tissue.

To understand neuropathy, it helps to understand how the nervous system works. Regenerative medicine is an emerging field, which offers a non-surgical option that commonly uses the patients own stem cells, exosomes, and other sources of growth factors to regenerate healthy tissue.

Erectile Dysfunction (ED) is the inability to achieve or maintain an erection sufficient for satisfactory sexual intercourse. Regenerative medicine is an emerging field, which offers a non-surgical option that commonly uses the patients own stem cells, exosomes, and other sources of growth factors to regenerate healthy tissue.

Stem Cell Center of NJ specializes in the non-surgical care of acute and chronic pain conditions in the orthopedic field whether its shoulder pain, elbow pain or ankle pain as well as the treatment of erectile dysfunction. In our facility, we utilize the latest research and technology to deliver the best treatment available. Our goal is to help patients restore function and mobility, reduce pain, and ultimately return them back to a life uninhibited by debilitating conditions.

We are very excited to offer our patients Stem Cell Therapy treatments. With Stem Cell Therapy, we harness the bodys innate healing potential to aid in the regeneration and restoration of injured or damaged body tissue. This is a minimally-invasive procedure that utilizes biologics harvested straight from the patient. This means that risk of rejection and infection is extremely rare!

With Stem Cell Therapy, patients no longer have to take heavy medication, endure risky surgical procedures or deal with long recovery periods and months of physical therapy. We have helped numerous patients throughout New Jersey get their lives back with Stem Cell Therapy will you be next?

Read more here:
Stem Cell Center Of NJ - New Jersey Stem Cell Therapy

Stem Cell Transplants | MD Anderson Cancer Center

A stem cell transplant is a procedure that replaces defective or damaged cells in patients whose normal blood cells have been affected by cancer.Stem cell transplants commonly are used to treat leukemia and lymphoma, cancers that affect the blood and lymphatic system. They also can help patients recover from or better tolerate cancer treatment.

In addition, these stem cell transplants are used to treat hereditary blood disorders, such as sickle cell anemia, and autoimmune diseases, such as multiple sclerosis.

Stem cell transplants use hematopoieticstem cells. These immature cells begin life in the bone marrow and eventually develop into the various types of mature blood cells, including:

There are two types of stem cell transplantation:

Cells are harvested from the patient's own bone marrow before chemotherapy and are replaced after cancer treatment. These are used most often to treat diseases like lymphoma and myeloma. They have little to no risk of rejection or graft versus host disease (GVHD) and are therefore safer than allogeneictransplants.

Stem cells come from a donor whose tissue most closely matches the patient.These cells can also come from umbilical cord blood extracted from the placenta after birth and saved in special cord blood banks for future use. MDAnderson's Cord Blood Bank actively seeks donations of umbilical cords.

Allogeneic transplants are often used to treat diseases that involve bone marrow, such as leukemia. Unlike autologous transplants, they generate a new immune system response to fight cancer. Their downside is an increased risk of rejection or GVHD.

Stem cell transplant patients are matched with eligible donors by human leukocyte antigen (HLA) typing. HLA are proteins that exist on the surface of most cells in the body. HLA markers help the body distinguish normal cells from foreign cells, such as cancer cells.

HLA typing is done with a patient blood sample, which is then compared with samples from a family member or a donor registry. It can sometimes take several weeks or longer to find a suitable donor.

The closest possible match between the HLA markers of the donor and the patient reduces the risk of the body rejecting the new stem cells (graft versus host disease).

The best match is usually a first degree relative (children, siblings or parents). These can be full matches or half-match related transplants, also known as haploidentical transplants.However, about 75% of patients do not have a suitable donor in their family and require cells from matched unrelated donors (MUD), who are located through registries such as the National Marrow Donor Program.

Because the patients immune system is wiped out before a stem cell transplant, it takes about six months to a year for the immune system to recover and start producing healthy new blood cells. Transplant patients are at increased risk for infections during this time, and must take precautions. Other side effects include:

Read this article:
Stem Cell Transplants | MD Anderson Cancer Center

Northern California Stem Cell Treatment Center in Redding, CA

100+ Treatments In The Last Year Alone In Redding

This practice is dedicated to cutting edge, highly professional procurement and delivery of autologous mesenchymal stem cells. This field is exciting for us, as well as for our affiliated physicians, and being able to offer such innovative stem cell therapy is a privilege, though it comes with great responsibility.

The Northern California Stem Cell Treatment Center is partnered with a large global organization called Cell Surgical Network. This affiliation, involving over 50 centers worldwide, shares our passion for this work and allows our practice and our patients the ability to add consequentially to the scientific knowledge base in clinical stem cell treatments.

We are pleased to be able to utilize our over 90 years of combined experience and expertise in treating patients to help forge progress in this exciting type of medicine, and we are dedicated to safely delivering stem cell therapy to our patients. We've been treating patients in Redding for over a year and seen more than 100 cases come through our office.Though the advancements thus far have been phenomenal,we are on the cusp of even greater life-changing medical innovations.

Here is the original post:
Northern California Stem Cell Treatment Center in Redding, CA

Researchers Hope Zika Virus Can Treat Deadly Brain Cancer – Healthline

Researchers have discovered that the Zika virus can kill tumor cells from glioblastoma cancers. Heres how it does that.

The Zika virus is known to attack the developing brain of fetuses, leaving infants at risk for severe birth defects.

But scientists are now hoping they can harness this dangerous virus to reach the brain in adults and kill hard-to-treat tumors.

The Zika virus swept through the Western hemisphere last year infecting millions and resulting in thousands of infants being born with the birth defect microcephaly.

The virus ability to reach the brain in utero has also led researchers to theorize it could potentially be used to fight a malignant form of brain cancer in adults, called glioblastoma.

In a new study, published in the Journal of Experimental Medicine, researchers from Washington University School of Medicine, the Cleveland Clinic, University of San Diego, and other institutions studied how human glioblastoma cells reacted to exposure to the Zika virus.

They also infected mice with glioblastomas to the virus to see if the infection affected the tumor.

Glioblastomas are the most common form of primary brain cancer, or cancer that has not metastasized from other areas of the body.

Every year approximately 12,000 people are diagnosed with the condition. This year Arizona Senator John McCain made headlines with his glioblastoma diagnosis.

Its a malignant form of cancer that kills most people within two years of diagnosis, even after surgery, chemotherapy, and radiation treatment.

In this study, the researchers wanted to see if Zika could potentially be used as a treatment to buy patients more time.

They exposed 18 mice with glioblastomas to the Zika virus and found that within two weeks the tumors were far smaller than those in the control group.

Additionally, they found that when they injected the virus into tumor cells, the virus infected and killed the stem cells in the tumor.

The findings are still preliminary, and the authors point out these findings would need to be replicated in patients with glioblastoma to verify the effects of the virus on these cancer cells.

Scientists hope these early results could mean that the Zika virus could be used in the future to help fight against glioblastoma.

We see Zika one day being used in combination with current therapies to eradicate the whole tumor, Dr. Milan G. Chheda, a senior author of the study and an assistant professor of medicine and neurology at Washington University School of Medicine, said in a statement.

Dr. Andrew Sloan, director of the Brain Tumor and Neuro-Oncology Center at University Hospitals Cleveland Medical Center, said that a patient with glioblastoma will usually have surgery to remove the tumor.

However, not even the best surgeon can get every microscopic cancer cell in the brain.

Ninety-eight percent of the patients will die of the tumor, and 90 percent will have the tumor grow back between 1 to 2 centimeters of the primary tumor, he explained.

Sloan explained that doctors believe its the stem cells which make up a small fraction of tumor cells that can cause the tumor to quickly grow back.

Cancer stem cells might compromise between 2 to 5 percent of all the cells in the tumor, Sloan told Healthline. But these are cells that are very resistant to radiation and chemotherapy, and these are the cells that give rise to new tumors.

Sloan said if the Zika virus targets the stem cells it might mean that the cancer doesnt return in patients after surgery.

Sloan said doctors have been hoping to find a way to harness a virus to prime the immune system to fight cancer, but so far nothing has been a game changer for glioblastoma treatment.

Theres been a lot of progress in immunotherapy, Sloan said. We think thats probably the best bet, but we havent hit anything over the fence.

He said he hopes that this early study could be the starting point for more research that could find a way to turn a deadly virus into a treatment.

Its very exciting and I think theres a lot of potential for it, he said.

Link:
Researchers Hope Zika Virus Can Treat Deadly Brain Cancer - Healthline

‘Nanotransfection’ Turns Animal Skin into Blood Vessels and Brain Cells – Medical Device and Diagnostics Industry

Nancy Crotti

Researchers have developed tissue nanotransfection, a process for regrowing tissue inside the human body.

Researchers at Ohio State University have developed breakthrough stem cell technology that can regrow tissue inside the human body, rather than in a laboratory.

Their work has implications for critical limb ischemia, brain disorders, and possibly even organ engineering and bone regrowth, according to Chandan Sen, PhD, director of the Center for Regenerative Medicine and Cell-Based Therapies at Ohio State's Wexner Medical Center in Columbus. Sen led the team that developed the technology.

Here's how the process, known as nanotransfection, works: The scientists make synthetic RNA and DNA to match that of the patient. They load it into nanochannels inside tiny needles embedded in a chip and apply the chip to the skin. The needles electrocute about 2% of the cell surface with the patient's nucleic acid. The procedure takes 1/10th of a second, and has been shown to work with up to 98% efficiency.

In experiments on mice, the technology restored blood flow to injured legs by reprogramming the animals' skin cells to become vascular cells. With no other form of treatment, active blood vessels had formed within two weeks, and by the third week, blood flow returned and the legs of the mice were saved.

The researchers also induced strokes in mice and used the chips to grow new brain tissue from the animals' skin and transplant it to their brains. Bodily function damaged by the strokes was restored. The study of the technique, which worked with up to 98% efficiency, was reported in the journal Nature Nanotechnology.

The technology marks an advance over cell regeneration conducted in a laboratory, because those cells mostly underperform or die once transplanted into the body, according to Sen. The researchers use skin cells in their work because, as Sen explained, everybody has some to spare.

"We grow it in you and we move it over to the organ so you have your own cells populating your organ," he said. "It's all coming from you."

The synthetic RNA and DNA reprogram cells in the same way that fetal cells develop different functions to become different body parts, Sen added. The researchers worked on the technology for more than four years, also conducting successful blood flow restoration experiments on pigs. When they begin human trials, their first patients will likely be those whose critical limb ischemic has reached the stage where amputation is the only option.

The scientists' work has generated interest in Europe, Asia, the Middle East, and in the United States. Ohio State will decide where to pursue human trials first, and is searching for industry partners.

"The cost is extremely low and complexity-wise it is extremely low. I see very little barrier to take it to humans," Sen said.

The researchers' work marks another interface between silicon chips and biology. Other applications picked up by manufacturers include DNA sequencing machines, miniaturized diagnostic tests using disposable photonic chips, accurate body monitoring sensors, and brain stimulation probes.

Sen and his team acknowledge that their work will be met with skepticism.

"Whenever you do something that is sort of transformative, you will expect that," Sen said. "Therefore, we actually published this in the most rigorous journal possible. We went through 16 months of criticism and response, after which this was published."

Nancy Crotti is a freelance contributor to MD+DI.

[Image courtesy of THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER]

Read the original:
'Nanotransfection' Turns Animal Skin into Blood Vessels and Brain Cells - Medical Device and Diagnostics Industry

Dr. Pawel Muranski to Head New Cellular Immunotherapy Laboratory at NewYork-Presbyterian/Columbia University … – Newswise (press release)

Newswise New York (August 31, 2017) Scientific innovator and physician Dr. Pawel Muranski has joined NewYork-Presbyterian and Columbia University Medical Center (CUMC) as director of cellular immunotherapy at the newly established Good Manufacturing Practices (GMP) cell production lab and assistant director of Transfusion Medicine and Cellular Therapy. He will also serve on the faculty of CUMC as Assistant Professor of Medicine, Pathology and Cell Biology, a principal investigator at Columbia Center for Translational Immunology (CCTI) and a member of Columbias Herbert Irving Comprehensive Cancer Center.

Were thrilled to have Dr. Muranski joining us to continue his innovative work, said Dr. Gary Schwartz, chief of the Division of Hematology/Oncology at NewYork-Presbyterian/CUMC and the Clyde 56 and Helen Wu Professor of Oncology (in medicine) at CUMC. His approach to T cell-based therapy holds so much potential and could revolutionize care for cancer patients, transplant patients and others.

Dr. Muranski is a hematologist who specializes in bone marrow transplantation and in developing adoptive T cell therapies, in which white blood cells called T lymphocytes are removed from a patient or a donor and then programmed to target viral infections, leukemic cells and solid tumors. Adoptive transfer of T cells, including Chimeric Antigen Receptor (CAR)-T therapy has shown great promise in early trials of patients with leukemia, lymphoma and several solid cancersin some cases leading to a complete remission.

Dr. Muranskis research will continue to focus on exploiting and enhancing the capability of engineered T cells to recognize and target cancerous cells or dangerous viruses. He has a particular interest in developing CD4+ T helper cellsthe master orchestrators of immune responseas a potentially powerful weapon against cancer. His T cells can also target viral infections in patients whose immune systems have been weakened by bone marrow or organ transplantation, cancer treatment, or autoimmune diseases.

Despite recent spectacular advances in the field of cancer immunotherapy, very few institutions have GMP laboratories with the capacity to grow and manipulate T cells, said Dr. Muranski. NewYork-Presbyterian and Columbia University Medical Center are now positioned to become leaders in cutting-edge cellular immunotherapies. Im excited to work with the team here on developing a comprehensive program that brings these innovative treatments to our patients.

In addition to his work in the GMP lab, Dr. Muranski will be working with Dr. Prakash Satwani, a pediatric hematologist and oncologist at NewYork-Presbyterian and associate professor of pediatrics at CUMC, on an upcoming major CAR-T cell initiative. He will also work closely with Dr. Markus Mapara, director of the Adult Blood and Marrow Transplantation Program at NewYork-Presbyterian/Columbia and professor of medicine at CUMC.

Dr. Muranski trained as a fellow at the Surgery Branch, National Cancer Institute (NCI), National Institutes of Health (NIH) in Bethesda, Maryland, where he performed innovative studies aimed at understanding of the role of CD4+ T cells as mediators of curative anti-tumor immunity. Most recently, he served in Hematology Branch, National Heart, Lung and Blood Institute (NHLBI) at the NIH, where his research focused on using T cell-based therapies to prevent viral infections in patients undergoing donor-based stem cell transplantation for blood cancers.

He earned his medical degree from the Medical University of Warsaw in Poland before completing a research fellowship at the Institute for Molecular Medicine and Genetics, Medical College of Georgia and a residency at St. Francis Hospital in Evanston, Illinois. He completed a clinical fellowship in hematology and oncology at the National Institutes of Health in Bethesda, Maryland.

NewYork-Presbyterian

NewYork-Presbyterian is one of the nations most comprehensive, integrated academic healthcare delivery systems, whose organizations are dedicated to providing the highest quality, most compassionate care and service to patients in the New York metropolitan area, nationally, and throughout the globe. In collaboration with two renowned medical schools, Weill Cornell Medicine and Columbia University Medical Center, NewYork-Presbyterian is consistently recognized as a leader in medical education, groundbreaking research and innovative, patient-centered clinical care.

NewYork-Presbyterian has four major divisions:

Columbia University Medical Center

Columbia University Medical Centerprovides international leadership in basic, preclinical, and clinical research; medical and health sciences education; and patient care. The medical center trains future leaders and includes the dedicated work of many physicians, scientists, public health professionals, dentists, and nurses at the College of Physicians and Surgeons, the Mailman School of Public Health, the College of Dental Medicine, the School of Nursing, the biomedical departments of the Graduate School of Arts and Sciences, and allied research centers and institutions. Columbia University Medical Center is home to the largest medical research enterprise in New York City and State and one of the largest faculty medical practices in the Northeast. The campus that Columbia University Medical Center shares with its hospital partner, NewYork-Presbyterian, is now called the Columbia University Irving Medical Center. For more information, visit cumc.columbia.eduorcolumbiadoctors.org.

Excerpt from:
Dr. Pawel Muranski to Head New Cellular Immunotherapy Laboratory at NewYork-Presbyterian/Columbia University ... - Newswise (press release)

FDA announces first US gene therapy approval for cancer treatment – CNN

The treatment, called Kymriah, aims to give some patients a second chance after first-line drugs have failed. This may happen in up to a fifth of patients, according to the FDA.

Each dose of Kymriah contains a patient's own immune cells, which are sent to a lab to be genetically modified using a virus. This therapy -- known as chimeric antigen receptor T-cell therapy, or CAR-T -- gives the cells the ability to recognize and kill the source of the cancer.

"We've never seen anything like this before and I believe this therapy may become the new standard of care for this patient population," said Dr. Stephan Grupp, director of cancer immunotherapy at Children's Hospital of Philadelphia, which spearheaded this research.

Based on available data, patients on the treatment have had an 89% chance of surviving at least six months and a 79% chance of surviving at least a year, with most being relapse-free at that point.

Most patients with ALL recover through other treatments such as radiation, chemotherapy and stem cells. But if the cancer recurs, the prognosis is poor.

"Kymriah is a first-of-its-kind treatment approach that fills an important unmet need for children and young adults with this serious disease," Dr. Peter Marks, director of the FDA's Center for Biologics Evaluation and Research, said in a statement.

The one-time treatment has a boxed warning for cytokine release syndrome or CRS, a life-threatening side effect that can cause blood pressure to drop dangerously low. It is caused by overactive genetically modified immune cells. The FDA said hospitals and clinics must become certified to distribute the treatment, meaning they are prepared to recognize and treat CRS and other potentially fatal neurological events. Novartis said it hopes to have an initial network of 20 treatment centers within a month with plans to expand that to 32 by the end of the year.

Kymriah has a $475,000 price tag; however, patients who do not respond within a month of treatment will not be charged, according to Novartis.

"Novartis is collaborating with (Centers for Medicaid Services) to make an outcomes-based approach available to allow for payment only when pediatric and young adult ALL patients respond to Kymriah by the end of the first month. Future potential indications would be reviewed for the most relevant outcomes-based approach," the drug company said in a statement.

On Wednesday, the FDA also expanded approval for another drug, tocilizumab, to treat CRS in patients 2 and older.

Novartis is required to conduct followup study to assess the safety of the treatment long-term.

The rest is here:
FDA announces first US gene therapy approval for cancer treatment - CNN

‘Reprogrammed’ Stem Cells Fight Parkinson’s Disease in Monkeys – Voice of America

LONDON

Scientists have successfully used "reprogrammed" stem cells to restore functioning brain cells in monkeys, raising hopes the technique could be used in the future to help patients with Parkinson's disease.

Since Parkinson's is caused by a lack of dopamine made by brain cells, researchers have long hoped to use stem cells to restore normal production of the neurotransmitter chemical.

Now, for the first time, Japanese researchers have shown that human induced pluripotent stem cells (iPS) can be administered safely and effectively to treat primates with symptoms of the debilitating disease.

So-called iPS cells are made by removing mature cells from an individual often from the skin and reprogramming them to behave like embryonic stem cells. They can then be coaxed into dopamine-producing brain cells.

The scientists from Kyoto University, a world-leader in iPS technology, said their experiment indicated that this approach could potentially be used for the clinical treatment of human patients with Parkinson's.

In addition to boosting dopamine production, the tests showed improved movement in affected monkeys and no tumors in their brains for at least two years.

The human iPS cells used in the experiment worked whether they came from healthy individuals or Parkinson's disease patients, the Japanese team reported in the journal Nature on Wednesday.

"This is extremely promising research demonstrating that a safe and highly effective cell therapy for Parkinson's can be produced in the lab," said Tilo Kunath of the MRC Center for Regenerative Medicine, University of Edinburgh, who was not involved in the research.

The next step will be to test the treatment in a first-in-human clinical trial, which Jun Takahashi of Kyoto University told Reuters he hoped to start by the end of 2018.

Any widespread use of the new therapy is still many years away, but the research has significantly reduced previous uncertainties about iPS-derived cell grafts.

The fact that this research uses iPS cells rather human embryonic stem cells means the treatment would be acceptable in countries such as Ireland and much of Latin America, where embryonic cells are banned.

Excitement about the promise of stem cells has led to hundreds of medical centers springing up around the world claiming to be able to repair damaged tissue in conditions such as multiple sclerosis and Parkinson's.

While some treatments for cancer and skin grafts have been approved by regulators, many other potential therapies are only in early-stage development, prompting a warning last month by health experts about the dangers of "stem-cell tourism."

Go here to see the original:
'Reprogrammed' Stem Cells Fight Parkinson's Disease in Monkeys - Voice of America

Frawley, Mindell/Brody, Calkins Awards Recognize 5 for Excellence – UB School of Medicine and Biomedical Sciences News

Resident Asma Mursleen, MD (center) with Roseanne C. Berger, MD (left), and Michael E. Cain, MD was honored for her research at the 20th annual Scholarly Exchange Day.

Published August 30, 2017

Trainees and a student in the departments of Medicine, Biomedical Engineering and Pediatrics have received awards for their research.

The two trainees to receive support from theThomas F. Frawley, MD, Residency Research Fellowship Fundare:

Asma Mursleen, MD Resident in theDepartment of Medicine Project Title: Defining the Role of CDC-derived Exosomes on Macrophage Polarization and Modulation of Cardioprotection Following Myocardial Infarction

Amanda Przespolewski, DO A 2017 alumna of the hematology/oncology fellowship Project title: Dual Enhancement of Immune Responses and Inhibition of Marrow Vasculature in Acute Myeloid Leukemia

The awardsupports medical or surgical residents, fellows and new graduates for whom research represents a primary interest and passion.

Frawley, a 1944 graduate of the medical school, was a nationally recognized endocrinology researcher, president of the American College of Physicians and chair of medicine at Saint Louis University School of Medicine.

The 2017 recipients of the Eugene R. Mindell, MD, and Harold Brody, MD 61, PhD, Clinical Translational Research Awardare:

Yongho Bae, PhD Assistant professor in theDepartment of Pathology and Anatomical Sciences Project Title: Effect of Arterial Stiffening on Vascular Smooth Muscle Cell Mechanotransduction

Kyle Indiana Mentkowski Masters candidate in the Department of Biomedical Engineering Project Title: Development of a Targeted Cardiomyocyte Delivery System Utilizing Cardiosphere-Derived Cell Exosomes

The award recognizes junior research scientists for the best basic science research that seeks to solve a clinical problem.

Mindell chairedUBs Department of Orthopaedics from 1964 to 1988. A past president of the American Board of Orthopaedic Surgery, he is credited withinitiating the boards certifying process for orthopaedic surgeons.

Brody was the chair of anatomy and cell biology from 1971 to 1992. He founded UBs Brain Museum, a world-class collection of brain specimens and slides.

The 2017 honorees for the Evan Calkins, MD, Fellowship for Community-Based Researchare:

Raed Al Yacoub, MD Resident in the Department of Medicine Project Title: Enhancing the Prevention of Microvascular Complications of Diabetes Type 2: A Resident-Led QI Project

Prerana Baranwal, MD Resident in the Department of Pediatrics Project Title: Addressing Childhood Obesity Through Dyslipidemia Screening: Measuring Frequency of Dyslipidemia Screening with Substitution of Random Lipid Panel for Fasting Lipid Panel

The award supports residents, fellows and junior faculty who conduct community-based research or quality improvement projects.

Calkins was chair of the UB Department of Internal Medicine, division chief of geriatrics and founder of the geriatrics fellowship. He served as director of medicine at Meyer Memorial Hospital (now Erie County Medical Center) for 12 years.

The award is a product of his conviction that medical institutions have an obligation to improve the quality of, and access to, health care throughout the community.

Amro Elshoury, MBBCh, a trainee in the hematology/oncology fellowship, received an honorable mention for the Frawley award. Elshourys project was: The Effect of Extra-Physiologic Oxygen Shock / Stress (EPHOSS) On Human Bone Marrow Stem Cell Viability And Multi-Potency.

Roseanne C. Berger, MD, senior associate dean for graduate medical education, presented the awards at this years Scholarly Exchange Day.

The keynote speaker,Steven D. Schwaitzberg, MD, professor and chair of surgery, presented a talk titled Preparing Students and Residents for 21st Century Surgery.

Michael E. Cain, MD, vice president for health sciences and dean, Jacobs School of Medicine and Biomedical Sciences, gave school updates and introductory remarks at the event.

Continue reading here:
Frawley, Mindell/Brody, Calkins Awards Recognize 5 for Excellence - UB School of Medicine and Biomedical Sciences News

CSL Behring pays $91M upfront for early stage gene therapy – BioPharma Dive

Dive Brief:

CSL Behring's pipeline and product portfolio focuses around immunodeficiency and autoimmune diseases, bleeding disorders, hereditary angioedema and hereditary emphysema.The purchase of Calimmune has benefits from two perspectives. It provides CSL Behring with an existing candidate that fits into one of the company's key therapeutic areas, and it also gives the company access to two platforms that will allow the company a route into developing its own ex vivo hematopoietic stem cell (HSC) gene therapies.

"Calimmune's scientific accomplishments are impressive," said CSL Behring's CEO Paul Perreault. "The team has built a robust technology platform, and designed a promising HSC gene therapy candidate - CAL-H, which strongly aligns with our longer-term strategic goals, and complements our core competencies and areas of therapeutic focus. While Calimmune is still in the early stages, we believe that our combined strengths have tremendous potential to change treatment paradigms, and most importantly, significantly improve the lives of our patients."

Calimmune has a deal with Cincinnati Childrens Hospital Medical Center, to combine its Select+ technology with the hospital's proprietary gene therapy construct for the treatment of patients with sickle cell disease and beta thalassemia. The Select+ technology positively selects for the modified HSCs. Calimmune is also developing gene therapies for undisclosed hemoglobinopathies.

In 2013, Calimmune began treating HIV-positive patients with a gene-based stem cell therapy in a Phase 1/2 trial, with the aim to protect them from the impact of the virus by blocking CCR5. Treatment of a second batch began in mid-2014.

See the original post here:
CSL Behring pays $91M upfront for early stage gene therapy - BioPharma Dive